• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Masimo Corporation

    6/25/25 6:45:01 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    11-K 1 masi-20250625x11k.htm 11-K Document
    Table of Contents
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    _____________________________
    FORM 11-K
    _____________________________
     
     
    (Mark One)
    ýANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2024
    OR
     
    ¨TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from                     to                     
    Commission File Number 001-33642
    _____________________________
     

     
    A.Full title of the plan and the address of the plan, if different from that of the issuer named below:
    image1.jpg
    MASIMO
    RETIREMENT SAVINGS PLAN
     
    B.Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
    MASIMO CORPORATION
    52 Discovery
    Irvine, California 92618














    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULE
    TABLE OF CONTENTS
     
    Report of Independent Registered Public Accounting Firm – Grant Thornton LLP
    3
    Financial Statements:
    Statements of Net Assets Available for Benefits as of December 31, 2024 and December 31, 2023
    4
    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2024
    5
    Notes to Financial Statements
    6
    Supplemental Schedules:
    Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions
    12
    Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)
    13
    Signature
    15



    Table of Contents
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    Plan Administrator and Plan Participants
    Masimo Retirement Savings Plan
    Opinion on the financial statements
    We have audited the accompanying statements of net assets available for benefits of Masimo Retirement Savings Plan (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.
    Basis for opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
    Supplemental information
    The supplemental information in the accompanying schedules, Schedule H, Line 4(a) - Schedule of Delinquent Participant Contributions for the year ended December 31, 2024 and Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year) as of December 31, 2024 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.
    /s/ GRANT THORNTON LLP

    We have served as the Plan’s auditor since 2010.
    Boston, Massachusetts
    June 25, 2025

    3

    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
     
     As of December 31,
     20242023
    ASSETS
    Investments, at fair value$241,748,178 $204,331,975 
    Receivables:
           Notes receivable from participants2,340,752 1,840,805 
           Due from broker for unsettled securities sold— 3,877 
                  Total receivables2,340,752 1,844,682 
    Net assets available for benefits$244,088,930 $206,176,657 
    The accompanying notes are an integral part of these financial statements.

    4

    Table of Contents


    MASIMO
    RETIREMENT SAVINGS PLAN
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
     
     Year Ended
     December 31, 2024
    ADDITIONS TO NET ASSETS
    Contributions:
           Participant deferral contributions$17,004,357 
           Participant rollover contributions1,321,316 
           Employer contributions4,594,160 
                  Total contributions22,919,833 
    Investment income:
           Dividends7,672,673 
           Net appreciation in fair value of investments26,511,536 
                  Net investment income34,184,209 
    Interest income on notes receivable from participants163,399 
                            Total additions to net assets57,267,441 
    DEDUCTIONS FROM NET ASSETS
    Distributions to participants19,182,012 
    Plan administrative expenses173,156 
                            Total deductions from net assets19,355,168 
    Net increase in net assets available for benefits37,912,273 
    Net assets available for benefits, at beginning of year206,176,657 
    Net assets available for benefits, at end of year$244,088,930 
    The accompanying notes are an integral part of these financial statements.

    5

    Table of Contents

    MASIMO
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023

    1. Description of the Plan
    The following description of the Masimo Retirement Savings Plan (the Plan) is provided for general information purposes only. Plan participants should refer to the Plan document for more complete information.
    General
    The Plan is a cash deferred arrangement under Section 401(k) of the Internal Revenue Code of 1986, as amended (the Code), covering U.S. employees of Masimo Corporation (the Company, Employer or Masimo) or one of its U.S. subsidiaries. The Plan was established for the purpose of providing retirement benefits for U.S. employees of the Company. The Plan is intended to qualify as a profit sharing plan under Section 401(a) of the Code with a salary reduction feature qualified under Section 401(k) of the Code. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA). The Plan is administered by the 401(k) Committee (Plan Management), members of which are appointed by the Company’s Board of Directors. Fidelity Management Trust Company (Fidelity) is a fiduciary of the Plan and also serves as the record keeper to maintain the individual accounts of each Plan participant. The Plan was originally adopted in April 1995, and has been amended at various times through December 31, 2024.
    Eligibility
    Employees who are at least 18 years of age and on the U.S. payroll of the Company or its U.S. subsidiaries are eligible to participate in the Plan as of the first date of employment with the Company or one of its U.S. subsidiaries, and are eligible to contribute to the Plan on the first day of the month concurrent with or following the first date of employment.
    Contributions
    Employees may elect to defer a percentage of their eligible compensation into the Plan. Compensation deferrals cannot exceed the maximum deferral, as determined by the Internal Revenue Service (IRS) each year. Such deferral limitation was 80% of compensation up to a maximum deferral of $23,000 in 2024. Employees who attained the age of 50 on or before December 31, 2024 were eligible to make additional catch-up contributions of up to $7,500 during 2024.
    During the year ended December 31, 2024, the Company matched 100% of a participant’s salary deferral, up to a maximum deferral of 3% of each participant’s eligible compensation for the pay period, subject to the annual compensation limit of $345,000 as determined by the IRS each year. The Company’s maximum aggregate matching contribution per participant was $10,350 in 2024. The Company has the right under the Plan to discontinue or modify its matching contributions at any time. In order to be eligible for matching contributions, a participant need not complete any service requirement. As of the year ended December 31, 2024, the Plan includes an employer match on catch-up contributions. In addition, the Plan includes an after-tax contribution provision, which allows participants to make annual after-tax contributions of up to 10% of their salary and is limited to 80% of compensation.
    Pursuant to the Plan Adoption Agreement, Matching Employer Contributions are made with each eligible participant’s contribution up to the match limits. At the end of each plan year, a true up calculation is performed and an additional Employer Contribution is made, as necessary, to ensure all eligible participant contributions are fully matched up to the full annual match limit for the full plan year.
    For the 2024 plan year, the additional true up employer match totaled $43,774, which was funded by forfeitures.
    The Company may also make discretionary contributions to the Plan in such amounts as determined by resolution of the Board of Directors. There were no discretionary contributions for the year ended December 31, 2024.
    Each eligible participant’s account is credited with (a) the participant’s contributions, (b) the Company’s matching contributions, and (c) an allocation of interest, dividends and any change in the market value of the various investment funds. Plan earnings, by investment fund, are allocated daily by the asset custodian on the basis of the ratio that each eligible participant’s account balance in the fund bears to the total account balances of all participants in the respective fund.
    6

    Table of Contents
    MASIMO CORPORATION
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023 - (Continued)
    Investment Options
    Participants direct the investment of their contributions and the Company’s matching contributions into various investment options offered by the Plan. The Plan currently offers investments in selected mutual funds, a Collective Investment Trust (CIT), and Masimo Corporation common stock.
    Vesting
    Participant contributions are fully vested when made. Participants in the Plan receive vesting credit for the Company’s matching contributions based upon years of service, beginning with the date of employment with the Company or one of its subsidiaries, as follows:
    Years of Service (Whole Years)Vesting
    Less than 20 %
           250 %
           375 %
    4 or more100 %
    On June 6, 2022, the Plan was amended to reflect a change in the vesting schedule to 25% annual vesting beginning after one year of service, and then an additional 25% for each additional year of service thereafter. This change only applies to active Plan participants with any amount of service time on or after June 1, 2022.
    Years of Service (Whole Years)Vesting
    Less than 10 %
           125 %
           250 %
           375 %
    4 or more100 %
    Distributions and Payments of Benefits
    The normal retirement age is 65. Participants who incur a termination of employment prior to their normal retirement age are entitled to that portion of their Plan benefits earned to date, with vesting based upon the whole years of service credited as of the date of termination. In addition, “in-service” distributions may be requested by active employees that have reached age 59½, that have made rollover contributions into the Plan or that qualify for a financial hardship distribution in accordance with the Code.
    On December 29, 2022, the Securing a Strong Retirement Act of 2022 (the SECURE Act 2.0) was signed into law. The SECURE Act 2.0 contains over 90 new retirement provisions, with varying effective dates primarily beginning in 2023 and spanning through 2027. Included in the SECURE Act 2.0 provisions was a change to the age at which required minimum distributions must commence from 72 to 73 for individuals who attain age 72 on or after January 1, 2023, and from age 73 to 75 for individuals who attain age 73 on or after January 1, 2033. The SECURE Act 2.0 includes both required and optional elements, which the Plan administrator is currently evaluating and incorporating into the Plan’s policies.
    Plan Termination
    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and/or to terminate the Plan, subject to the provisions of ERISA. In the event of termination of the Plan, participants will become fully vested in their accounts.
    Forfeitures
    Forfeitures of terminated participants’ non-vested account balances may be used to pay administrative expenses or to reduce employer matching contributions. During the year ended December 31, 2024, no forfeitures were used to pay administrative expenses and $515,300 of forfeitures were used to reduce employer matching contributions. As of December 31, 2024 and December 31, 2023, the unallocated forfeiture balance was $221,774 and $251,752, respectively.
    7

    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023 - (Continued)
    Administrative Expenses
    Administrative expenses, which consist primarily of participant and recordkeeping fees, were paid directly from participants’ accounts. Certain administrative costs of the Plan were paid by the Company and not paid out of the Plan’s assets.
    Notes Receivable from Participants
    Notes receivable from participants are secured by the participant’s account balance and may not exceed the lesser of 50% of the participant’s account balance or $50,000 in the aggregate for any individual participant. The number of outstanding notes per participant is limited to one. Notes related to the purchase of a participant’s primary residence may not exceed a term of ten years. The term of all other notes may not exceed five years. For the year ended December 31, 2024, the annual interest rates of all notes outstanding ranged from 4.25% to 9.50%. For the year ended December 31, 2023, the annual interest rate of all notes outstanding ranged from 4.25% to 8.00%. Principal and interest are paid ratably through payroll deductions.
    2. Summary of Significant Accounting Policies
    Basis of Accounting
    The Plan’s financial statements are prepared on the accrual basis, in conformity with accounting principles generally accepted in the United States of America (GAAP).
    Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and changes therein, and disclosure of contingent assets and liabilities at the date of the financial statements.
    Risks and Uncertainties
    The Plan assets consist of various investments which are exposed to a number of risks, including interest rate, market and credit risks and Masimo Corporation common stock risks. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.
    Investment Valuation and Income Recognition
    The Plan’s investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Plan administrator determines the Plan’s valuation policies utilizing information provided by the investment advisers and custodians. See Note 3 for discussion of fair value measurements.
    Purchases and sales of investments are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are accrued on the ex-dividend date. Net appreciation in the fair value of investments includes the Plan’s net gains and losses on investments bought and sold, as well as held, during the year.
    Mutual funds and Masimo Corporation common stock are valued at the quoted market prices. Units of the CIT are valued at net asset value (NAV) as a practical expedient to fair value.
    Payment of Benefits
    Benefit payments to participants are recorded when paid.
    Contributions
    Contributions made by participants and the employer are recorded on an accrual basis. Contributions are recognized during the period in which the related compensation was earned by a participant.
    8

    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023 - (Continued)
    Notes Receivable from Participants
    Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Interest income is recorded on the accrual basis. Related fees are recorded as administrative expenses and are expensed when they are incurred. Delinquent loans are reclassified as distributions based upon the terms of the Plan document.
    3. Fair Value Measurements
    The authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
    •Level 1—Quoted prices in active markets for identical assets or liabilities.
    •Level 2—Inputs other than Level 1 that are observable, either directly or indirectly; such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
    •Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
    The following is a description of the valuation methodologies used by the Plan for assets measured at fair value. There have been no changes to the methodologies used at December 31, 2024 and December 31, 2023.
    Mutual Funds
    Mutual funds are valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are actively traded.
    Collective Investment Trust (CIT)
    The CIT invests in stable value investment contracts (Stable Value Contracts) issued by life insurance companies, banks and other financial institutions, fixed income instruments that underlie Stable Value Contracts and other money market instruments. Under a Stable Value Contract, the issuer of the contract agrees, subject to contract conditions, to make payments representing redemptions from the Fund for participant-initiated benefit payments at “contract value” which is generally equal to the principal plus accrued interest of the underlying investments. This “benefit responsiveness” is designed to allow the CIT to maintain participant balances at book value (except under certain circumstances set forth within the Stable Value Contracts) while the impact of market fluctuations on investor account balances is potentially smoothed via periodic adjustments to the daily rate of return credited to investors. The Plan has only one CIT, which is the Goldman Sachs Stable Value Collective Investment Trust Class IV. As a practical expedient, the fair value of the CIT is reported based on the NAV of the CIT units since such units are not actively traded on a public market. There is a twelve month notice period for the CIT that can be enforced by Goldman Sachs before allowing a complete redemption by the Plan and there were no unfunded commitments.
    9

    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023 - (Continued)
    Masimo Corporation Common Stock
    Masimo Corporation common stock is valued at the quoted closing market price from The Nasdaq Stock Market LLC.
    The following tables represent the Plan’s fair value hierarchy for its investments:
     Fair Value Measurements as of December 31, 2024
    Investment ClassLevel 1Level 2Level 3Total
    Mutual funds$215,511,841 $— $— $215,511,841 
    Masimo Corporation common stock22,596,425 — — 22,596,425 
        Total assets in fair value hierarchy$238,108,266 $— $— $238,108,266 
    Collective investment trust3,639,912 
        Total investments at fair value$241,748,178 
     
     Fair Value Measurements as of December 31, 2023
    Investment ClassLevel 1Level 2Level 3Total
    Mutual funds$184,700,029 $— $— $184,700,029 
    Masimo Corporation common stock16,069,417 — — 16,069,417 
        Total assets in fair value hierarchy$200,769,446 $— $— $200,769,446 
    Collective investment trust3,562,529 
        Total investments at fair value$204,331,975 

    4. Party-in-Interest Transactions
    Transactions in shares of Masimo’s common stock qualify as exempt party-in-interest transactions under the provisions of ERISA, since Masimo is the Plan administrator. During the year ended December 31, 2024, the Plan made purchases of $3,734,761 and sales of $3,668,358 of Masimo’s common stock on behalf of Plan participants.
    Fidelity is the trustee, custodian and record keeper as defined by the Plan, and therefore, the transactions with Fidelity investments qualify as party-in-interest transactions. Purchases and sales of these accounts and the underlying investments comprising these accounts are open market transactions at fair market value. Such transactions are permitted under the provisions of the Plan and are exempt from the prohibition of party-in-interest transactions under ERISA and applicable exemptions promulgated thereunder. Consequently, management fees and operating expenses are reflected as a reduction of investment return for such investments.
    In addition, notes receivable from participants are also considered to be party-in-interest transactions, which are exempt from the prohibited transaction rules under ERISA.
    5. Tax Status of the Plan
    The Plan is required to operate in conformity with the Code to maintain its qualification. The Plan is a Fidelity Volume Submitter Plan, which received a favorable advisory letter from the IRS in June 2020. The Plan administrator believes that the Plan is qualified under Section 401(a) of the Code and the related trust is tax-exempt as of December 31, 2024 and December 31, 2023. In accordance with GAAP, Plan Management is required to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2024 and December 31, 2023, there are no uncertain tax positions taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Plan’s tax returns generally remain open for IRS audit for three years from the filing date.
    10

    Table of Contents
    MASIMO
    RETIREMENT SAVINGS PLAN
    NOTES TO FINANCIAL STATEMENTS
    AS OF DECEMBER 31, 2024 AND 2023 - (Continued)
    6. Delinquent Participant Contributions
    For the years ended December 31, 2024 and December 31, 2023, the Company did not remit certain participant contributions to the Plan on a timely basis as defined by the Department of Labor’s Rules and Regulations for Reporting and Delinquent Participant Contributions Disclosure under ERISA. Untimely remittances identified on the Schedule of Delinquent Participant Contributions totaled $8,344 and $1,796 in 2024 and 2023, respectively. See accompanying supplemental Schedule H, Line 4(a) - Schedule of Delinquent Participant Contributions for further information.
    7. Subsequent Events
    Effective April 1, 2025, the Plan was amended to allow in-plan Roth conversions and in-plan Roth rollover contributions.
    Plan Management has evaluated all events or transactions that occurred through June 25, 2025, the date the financial statements were issued and determined that there are no additional matters requiring adjustment to or disclosure in the accompanying financial statements and related notes.
    11

    Table of Contents




    MASIMO CORPORATION
    RETIREMENT SAVINGS PLAN
    Supplementary Information
    Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions
    For the year ended December 31, 2024
    Participant Contributions Transferred Late to Plan
    Total that Constitute Nonexempt Prohibited TransactionsTotal Fully Corrected Under VFCP and
     Prohibited Transaction Exemption 2002-51
    Check here if Late Participant Loan
    Repayments are Included ☐
    Contributions Not Corrected(1)
    Contributions Corrected Outside Voluntary Fiduciary Correction Program (VFCP)
    Contributions Pending Correction in VFCP
    $8,344 $1,334 $— $— $7,010 
    _______________
    (1)    These delinquent contributions were fully corrected in February 2025.

    12

    Table of Contents

    MASIMO
    RETIREMENT SAVINGS PLAN
    EIN#: 33-0368882 PLAN#: 001
    Supplementary Information
    Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)
    As of December 31, 2024
    (a)(b)(c)(e)
     Identity of Issue, Borrower, Lessor or Similar PartyNumber of sharesValue
    Mutual Funds:
    *
    Fidelity® 500 Index Fund
    156,621 $31,980,425 
    American Funds 2035 Target Date Retirement Fund® Class R-6
    1,455,788 27,718,208 
    American Funds 2040 Target Date Retirement Fund® Class R-6
    1,107,566 22,771,560 
    American Funds 2030 Target Date Retirement Fund® Class R-6
    1,238,543 21,414,407 
    American Funds 2045 Target Date Retirement Fund® Class R-6
    897,471 19,026,382 
    American Funds 2055 Target Date Retirement Fund® Class R-6
    656,609 17,354,174 
    American Funds 2025 Target Date Retirement Fund® Class R-6
    1,139,217 17,304,700 
    American Funds 2050 Target Date Retirement Fund® Class R-6
    744,435 15,558,690 
    Vanguard Information Technology Index Fund Admiral Shares21,758 6,925,029 
    American Funds 2020 Target Date Retirement Fund® Class R-6
    408,317 5,495,946 
    *
    Fidelity® Mid Cap Index Fund
    138,770 4,686,257 
    PGIM Jennison Growth Fund Class R648,003 3,365,998 
    *
    Fidelity® Small Cap Index Fund
    110,781 3,066,428 
    *
    Fidelity® International Index Fund
    51,246 2,436,231 
    Victory Sycamore Established Value Fund Class I43,088 1,980,325 
    Columbia Select Large Cap Value Instl 349,458 1,754,765 
    *
    Fidelity® U.S. Bond Index Fund
    168,725 1,724,366 
    *
    Fidelity® Select Health Care Portfolio
    60,925 1,660,206 
    PIMCO Income Fund Institutional Class154,620 1,626,598 
    Victory Sycamore Small Company Opportunity Fund Class I19,375 913,906 
    American Funds 2015 Target Date Retirement Fund® Class R-6
    64,658 792,061 
    Putnam Small Cap Growth Fund Class R69,704 769,644 
    *
    Fidelity® Real Estate Investment Portfolio
    19,326 745,778 
    Invesco Global Opportunities Fund Class R614,762 727,039 
    BlackRock Mid-Cap Growth Equity Portfolio K16,473 717,876 
    American Funds New World Fund® Class R6
    8,666 667,016 
    *
    Fidelity® Emerging Markets Index Fund
    60,475 632,573 
    MFS International Diversification R6 Fund27,411 626,351 
    First Eagle Global Fund Class I6,231 420,038 
    Prudential Total Return Bond Fund Class Z31,158 368,285 
    PIMCO International Bond Fund (U.S. Dollar Hedged)23,571 234,059 
    American Funds 2010 Target Date Retirement Fund® Class R-6
    3,764 43,741 
    *
    Fidelity® Government Money Market Fund
    2,779 2,779 
        Total Mutual Funds$215,511,841 
    Collective Investment Trust:
    Goldman Sachs Stable Value Institutional Series Class I3,639,9123,639,912
    Common Stock:
    *Masimo Corporation136,666 22,596,425 
    Other:
    *Notes receivable from participantsAt interest rates between 4.25% and 9.50%, with scheduled maturity dates through December 20342,340,752 
        Total$244,088,930 
    * Indicates a party-in-interest to the Plan.
    Column (d), historical cost, has been omitted as all investments are participant directed.
    13

    Table of Contents
    EXHIBIT INDEX
     
    Exhibit
    Number
    Description of Document
    23.1
    Consent of Independent Registered Public Accounting Firm – Grant Thornton LLP

    14

    Table of Contents
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan administrator of the Masimo Retirement Savings Plan has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
     
      MASIMO RETIREMENT SAVINGS PLAN
    June 25, 2025  By:
    /s/ MICAH YOUNG
      Micah Young
      Executive Vice President, Chief Financial Officer of Masimo Corporation

    15
    Get the next $MASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

      EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure Masimo (NASDAQ:MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation

      6/10/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the Jefferies Global Healthcare Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 1:25 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower

      5/27/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the BofA Securities 2025 Health Care Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bo

      5/7/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on Masimo with a new price target

      Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

      12/27/24 7:29:29 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Raymond James with a new price target

      Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

      11/6/24 7:17:22 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

      6/3/24 7:31:43 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Muhsin Bilal exercised 10,000 shares at a strike of $34.51 and sold $1,632,781 worth of shares (10,000 units at $163.28) (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/14/25 5:32:56 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Solomon Darlene J. S. converted options into 1,790 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:55:57 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Scannell Timothy J converted options into 1,383 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:54:23 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    SEC Filings

    See more
    • SEC Form 11-K filed by Masimo Corporation

      11-K - MASIMO CORP (0000937556) (Filer)

      6/25/25 6:45:01 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MASIMO CORP (0000937556) (Filer)

      6/12/25 4:17:11 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Masimo Corporation

      SD - MASIMO CORP (0000937556) (Filer)

      5/27/25 5:27:13 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Financials

    Live finance-specific insights

    See more
    • Masimo Reports First Quarter 2025 Results

      Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First Quarter 2025 Results From Discontinued Operations(2): GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer busi

      5/6/25 4:10:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participant

      4/24/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

      Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue was $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue was $232 million, representing 11% growth on a reported and constant currency basis(1); GAAP net loss per basic share was ($6.52), which included an impairment of goodwill and intangibles for Sound United

      2/25/25 4:05:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care